Understanding access to novel high-cost cancer therapies across Canada: a national survey of pediatric oncology providers - Top-Institutions - MDSpire

Understanding access to novel high-cost cancer therapies across Canada: a national survey of pediatric oncology providers

  • By

  • Kriti Kumar

  • Avram Denburg

  • Celine Cressman

  • Derek S. Tsang

  • Marcel Romanick

  • Myanca Rodrigues

  • Paul J. Gibson

  • May 20, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    McMaster University
    McMaster University

    Hamilton, Ontario

    Key Differentiators

    • Pediatric Oncology

  • #2

    ACCESS (Advancing Childhood Cancer Experience, Science & Survivorship) network
    ACCESS (Advancing Childhood Cancer Experience, Science & Survivorship) network

    Toronto, Ontario

    Key Differentiators

    • Pediatric Oncology

  • #3

    C17 Council
    C17 Council

    Toronto, Ontario

    Key Differentiators

    • Pediatric Oncology

  • #4

    Canadian Association of Radiation Oncologists (CARO)
    Canadian Association of Radiation Oncologists (CARO)

    Ottawa, Ontario

    Key Differentiators

    • Pediatric Oncology

  • #5

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Pediatric Oncology

Original Source(s)

Understanding access to novel high-cost cancer therapies across Canada: a national survey of pediatric oncology providers

  • by Kriti Kumar, Avram Denburg, Celine Cressman, Derek S. Tsang, Marcel Romanick, Myanca Rodrigues, Paul J. Gibson

  • May 20, 2026

Related Content

Rethinking Progress in Clinical Trials

Three clinical development leaders discuss how early signals, trial design, regulatory expectations, and patient access are reshaping clinical development

  • May 20, 2026

  • 11 min
Roswell Park Experts Report on Discovery of Rare Bladder Cells, Neural Mapping of Pelvic Floor Muscles at AUA 2026

Evidence provided by a Roswell Park study indicates that neoadjuvant chemotherapy may be the preferred course of treatment for patients with non-muscle-invasive bladder cancer (NMIBC) when their disease progresses and they are diagnosed with muscle-invasive bladder cancer (MIBC)

  • by

  • May 19, 2026

  • 7 min
This Week’s Biopharma News: FDA Commissioner Steps Down

Marty Makary’s resignation puts the agency under acting leadership, while BMS and Hengrui unveil a multibillion-dollar pipeline deal and GSK lines up a chronic hepatitis B launch in China.

  • May 19, 2026

  • 4 min